Storys zum Thema Health

UCB Pharma

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease

Brussels (ots/PRNewswire) - - UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further ...

UCB Pharma

UCB Half Year Report 2020

Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...

Norgine; AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand

Waltham, Mass. and Amsterdam (ots/PRNewswire) - Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties Collaboration further advances the development of ciraparantag AMAG Pharmaceuticals, Inc. ...

Legal Team Armenia

The European Court of Human Rights requests the Government of Armenia to ensure adequate medical treatment to illegally detained former statesman Gagik Khachatryan

Viroclinics Biosciences

Davide Molho, DVM Joins Viroclinics Biosciences as Chief Executive Officer

Rotterdam, Netherlands (ots/PRNewswire) - Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company's CEO since 2011. This transition is part of a planned succession strategy. Dr. ...

Terumo

Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field

Tokyo and Deventer, Netherlands (ots/PRNewswire) - Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy (SIRT), a treatment for liver tumors. Under the terms of the agreement, ...

Daiichi Sankyo Europe GmbH

Rates of Bleeding and Venous Thromboembolism (VTE) Events Reported After 12 Months of Edoxaban Treatment Considered Low by Real-world ETNA-VTE Study Investigators

Munich (ots/PRNewswire) - - Daiichi Sankyo presented five abstracts from the Global and European ETNA-VTE registry studies at ISTH 2020 Virtual Congress - Data are from 4,595 VTE patients (mean age 64) from 583 sites across Europe, Japan and other East and South-east Asian countries - Real-world study adds to the ...

Merck Healthcare Germany

Stephan Sieber Awarded EUR 1 Million Future Insight Prize 2020 by Merck

Darmstadt, Germany (ots/PRNewswire) - - Prof. Sieber is developing approaches against multi-resistant pathogens at the Technical University of Munich - Inaugural Johann Anton Merck Award presented to Prof. Caroline Dive, Cancer Research UK, for her liquid biopsy research - Sibel Health awarded the Nature Spinoff Prize Merck, a leading science and technology company, ...

Effectory BV

Effectory: Good Crisis Communication Is Essential for Productivity During the Coronavirus Situation

Amsterdam (ots/PRNewswire) - Employees who are satisfied with the way in which their organization is handling the COVID-19 situation are able to perform 28 percent better. And during the first wave of coronavirus cases, sixty percent of employees experienced a poor work-life balance, an Effectory survey of 123,000 ...

Cancer Research UK; Abcam

Cancer Research UK and Abcam Launch Custom Partnership to Accelerate Cancer Research

London and Cambridge, England (ots/PRNewswire) - - Long-term partnership to facilitate cancer research through development of custom antibodies - Agreement to enable global access to resulting reagents and potential diagnostics Today, Cancer Research UK, the world's largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents ...

Pro Aidants

We+Care: EUR1.5 million to increase the quality at the end of life

CSL Behring

IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing

Hattersheim, Germany (ots/PRNewswire) - European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for IDELVION® ...

Carag

Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework

Baar, Switzerland (ots/PRNewswire) - The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) ...

Schweizerischer Nationalfonds / Fonds national suisse

Towards a Swiss Food Strategy for 2050

Bern (ots) - NRP 69 recommends that the government develop a Swiss Food Strategy for 2050. This strategy should enable the entire population to eat healthy food sourced from a sustainable production and distribution system. Is it possible to follow a healthy diet that includes more vegetables, fruit and nuts while still reducing the environmental impact that consumption has both in Switzerland and abroad? Funded by the ...

Gerresheimer AG

Annual General Meeting of Gerresheimer AG Approves Dividend Increase to EUR 1.20 per Share

Duesseldorf, Germany (ots/PRNewswire) - Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG. "In 2019, we paved the way for profitable growth and achieved a substantial improvement in the Company's culture and dynamic. We are investing and working to grow our innovation pipeline. These efforts continue ...

IgNova GmbH

IgNova files patent application on antibody against COVID-19

Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...

COMPASS Pathways

Mental Health Care Company COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer

London (ots/PRNewswire) - - Piers Morgan appointed earlier in the year as Chief Financial Officer and Gary Gilmour as Director of Preclinical Research COMPASS Pathways, a mental health care company, announced today that it has made a number of new appointments to its leadership team. Trevor Mill joins the company as ...

Zhejiang Hisun Pharmaceutical Co. Ltd

Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiravir

Taizhou, China (ots/PRNewswire) - Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly ...

Norgine GmbH

Norgine B.V. Senior Management Changes: Christopher Bath Appointed Chief Operating Officer

Amsterdam (ots/PRNewswire) - Norgine B.V. (Norgine) today announced that Christopher Bath has been appointed Chief Operating Officer (COO) effective 1st July 2020. Chris, who has been Norgine's Chief Financial Officer since 2014, will report to Peter Stein, Chairman and Chief Executive Officer (CEO) of Norgine. He will be responsible for all global operations. Chris ...

The International Osteoporosis Foundation (IOF)

New Capture the Fracture® partnership aims for 25% reduction in the incidence of hip and vertebral fractures due to osteoporosis by 2025

Novo Nordisk

Investigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Insulin Glargine U100 in Phase 2 Trial

Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the ...

Novo Nordisk

Switching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice

Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...

International Atherosclerosis Society

International Atherosclerosis Society Issues Call to Action to Improve Lipid Management Based on Survey Results to Address Patients' Residual Risk

Milan (ots/PRNewswire) - Article and slides can be found at https://www.athero.org/activities/survey or contact Karen Foy (karen.foy@athero.org) A new survey by the International Atherosclerosis Society (IAS) provided a 'snapshot' of the gaps in knowledge among clinicians that limit best practice. This web-based ...

Galderma

Galderma Global Research Reveals Struggles of People With Rosacea and Psoriasis of the Face Experiencing a Lack of Control and Impact on Mental Wellbeing

Lausanne, Switzerland (ots/PRNewswire) - Healthcare professionals (HCPs) encouraged to investigate true impacts beyond the visible, empower patients with knowledge and aim for 'clear' (IGA 0) skin to improve outcomes A new expert-authored Galderma report (https://hosted.bmj.com/rosaceabeyondthevisible) released ...